Our findings also revealed that high DCBLD2 expression levels were related to poorer PD1 outcomes in glioblastoma and melanoma, poorer CTLA4 outcomes in melanoma, and poorer PDL1 outcome in the bladder. The gene discussed is DCBLD2; the disease is melanoma.